HomeREGULATORY
REGULATORY

MHLW OKs Japan’s 1st PD-L1 Inhibitor, 8-Week Hep C Med, Ibrance and More
(Sep.28.2017)

The Ministry of Health, Labor and Welfare (MHLW) approved a throng of new medicines on September 27, including Japan’s first PD-L1 inhibitor Bavencio (avelumab) by Merck Serono and Pfizer, and AbbVie’s eight-week hepatitis C therapy Maviret (glecaprevir + pibrentasvir) ...
(LOG IN FOR FULL STORY)